肠道菌群与原发性肝癌

doi:10.3969/j.issn.1672-5069.2020.06.003

实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (6): 769-772.doi: 10.3969/j.issn.1672-5069.2020.06.003

肠道菌群与原发性肝癌

王飞雪, 于君

中国香港香港中文大学威尔斯亲王医院内科与药物治疗学系/消化疾病研究所/消化疾病研究国家重点实验室

收稿日期:2020-08-03 发布日期:2021-02-25
通讯作者: 于君,香港中文大学终身讲座教授,医学院助理院长、香港中文大学消化道肿瘤实验中心主任、消化疾病研究国家重点实验室副主任、长江学者讲座教授、美国胃肠病协会肿瘤常务理事、美国胃肠病协会微生态常务理事、香港科协副主席、香港免疫协会主席(2017-2018)。中国抗癌协会肿瘤与肠道微生物专业委员会副主任委员。担任Gut、Oncogene、J Gastroenterol Hepatol等10多个国际知名期刊的主编或编委。于君教授长期致力于消化系统肿瘤发生机制和防治研究,包括肠道微生态和肿瘤研究,获奖三十余项,包括何梁何利基金科学与技术进步奖(2018);美国胃肠病学会肿瘤研究导师奖(2017);药明康德生命化学研究奖(2017);国家自然科学二等奖(2016);国家创新团队奖(2016);国家科技进步二等奖(2012);香港裘槎卓越科研奖(2016);教育部自然科学奖一等奖(2014);教育部科技进步奖一等奖(2012);教育部自然科学奖一等奖(2010)。发表学术论文420余篇(SCI论文390余篇)。主编英文专著2部,参与编写专著12部。获得国内外专利40多项。传真:(852) 21445330,E-mail:junyu@cuhk.edu.hk
作者简介:王飞雪,女,27岁,博士研究生。主要从事消化道肿瘤与肠道菌群的相关研究。E-mail:fxwang93@link.cuhk.edu.hk

Gutmicrobiota in patients with hepatocellular carcinoma

Wang Feixue, Yu Jun

Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Diseases, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China SAR

Received:2020-08-03 Published:2021-02-25

摘要/Abstract

关键词: 原发性肝癌, 肠道菌群

Key words: Hepatocellular carcinoma, Gut microbiota

王飞雪, 于君. 肠道菌群与原发性肝癌[J]. 实用肝脏病杂志, 2020, 23(6): 769-772.

Wang Feixue, Yu Jun. Gutmicrobiota in patients with hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2020, 23(6): 769-772.

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol, 2014, 14(10): 667-685.
[3] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature, 2014, 513(7516): 59-64.
[4] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut, 2019, 68(6): 1014-1023.
[5] Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology, 2019, 69(1): 107-120.
[6] Mu Q, Kirby J, Reilly CM, et al. Leaky gut as a danger signal for autoimmune diseases. Front Immunol, 2017, 8: 598.
[7] de Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the link? Obes Rev, 2011, 12(6): 449-458.
[8] Stevenson BR, Siliciano JD, Mooseker MS, et al. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol, 1986, 103(3): 755-766.
[9] Furuse M, Fujita K, Hiiragi T, et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol, 1998, 141(7): 1539-1550.
[10] Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut, 2019, 68(8): 1516-1526.
[11] Higashi Y, Suzuki S, Sakaguchi T, et al. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. J Surg Res, 2007, 139(1): 68-76.
[12] Fedirko V, Tran HQ, Gewirtz AT, et al. Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study. BMC Med, 2017, 15(1): 72.
[13] Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell, 2012, 21(4): 504-516.
[14] Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 2018, 360(6391).
[15] Yu LX, Yan HX, Liu Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology, 2010, 52(4): 1322-1333.
[16] Loo TM, Kamachi F, Watanabe Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov, 2017, 7(5): 522-538.
[17] Sanchez B. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis: a role for bifidobacteria and lactobacilli? Nat Rev Gastroenterol Hepatol, 2018, 15(4): 205.
[18] Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol, 2018, 15(2): 111-128.
[19] Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature, 2013, 499(7456): 97-101.
[20] Singh V, Yeoh BS, Chassaing B, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell, 2018, 175(3): 679-694 e622.
[21] Zhang X, Coker OO, Chu SH et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut, 2020[ahead of print] .
[22] Cho EJ, Leem S, Kim SA, et al. Circulating microbiota-based metagenomic signature for detection of hepatocellular carcinoma. Sci Rep, 2019, 9(1): 7536.
[23] Li J, Sung CY, Lee N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A, 2016, 113(9): E1306-1315.

肠道菌群与原发性肝癌

Gutmicrobiota in patients with hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李晓燕, 胡和平. 加强肝癌内科队伍建设,重视肝癌内科规范化和个性化诊疗决策[J]. 实用肝脏病杂志, 2021, 24(1): 1-3.
[2]	周新民, 丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用[J]. 实用肝脏病杂志, 2021, 24(1): 4-6.
[3]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[4]	张雪, 胥莹, 安文慧, 张帮婷, 杨雪芳. 五种评分系统判断TACE术治疗原发性肝癌患者发生肝功能不全效能比较研究[J]. 实用肝脏病杂志, 2021, 24(1): 111-114.
[5]	乔敏, 赵一鉴, 张建巧, 景赟杭. TACE联合射频消融治疗原发性肝癌患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 119-122.
[6]	李亚敏, 王瑞婷, 王瑛瑛. 冷循环射频消融术治疗原发性肝癌患者疗效及外周血Treg细胞的变化观察[J]. 实用肝脏病杂志, 2021, 24(1): 123-126.
[7]	潘勤, 范建高. 肠源性高血氨在非酒精性脂肪性肝炎发病中的作用^*[J]. 实用肝脏病杂志, 2020, 23(6): 761-764.
[8]	郭文成, 李娜, 王芳, 张宁, 刘燕. TACE联合¹³¹I美妥昔单克隆抗体灌注治疗原发性肝癌患者近期疗效研究[J]. 实用肝脏病杂志, 2020, 23(6): 877-880.
[9]	胡侠, 翟笑枫, 顾伟, 卢成鸿. 射波刀联合经肝动脉化疗栓塞治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 881-884.
[10]	韩鹏伟, 王虎明, 赵天永. AFP阴性原发性肝癌临床特征及预后因素分析[J]. 实用肝脏病杂志, 2020, 23(5): 715-718.
[11]	郝莎莎, 任晓静, 原丽莉, 姚佳. 肝硬化患者肠道微生态与肌量减少的相关性研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 462-466.
[12]	齐敬聪, 邢文静, 杜洋, 高辰玮. 熊去氧胆酸联合微生态制剂治疗原发性胆汁性胆管炎患者对肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 524-527.
[13]	栗红江, 何福亮, 陈来印. 酒精性肝病患者血清LP、LPO、NOS水平和肠道菌群分布变化分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 536-539.
[14]	孟海生, 胡冬梅, 王海涛, 顾金凤, 赵静, 梁啸寒. 应用超声单模态融合成像技术指导微波消融治疗原发性肝癌即时疗效评价的价值研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 572-575.
[15]	全亚宁, 商晓杰, 孟璇, 高榆秀. 实时超声造影和融合影像导航下微波消融与手术治疗小肝癌患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(4): 581-584.